CCR2 genotype and disease progression in a treated population of HIV type 1-infected women

Sean Philpott, Harold Burger, Patrick M. Tarwater, Ming Lu, Stephen J. Gange, Kathryn Anastos, Mardge Cohen, Ruth M. Greenblatt, Andrea Kovacs, Howard Minkoff, Mary Young, Paolo Miotti, Michelle Dupuis, Barbara Weiser

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Both antiretroviral therapy and the human coreceptor polymorphism CCR2-V64I slow progression of human immunodeficiency virus type 1 (HIV-1) disease. To examine the effect of V64I on disease progression in patients receiving therapy, we determined CCR2 genotypes in the Women's Interagency HIV Study cohort. We studied 2047 HIV-1-infected women, most of whom initiated treatment during the study. No association was seen between CCR2 genotype and either disease progression or therapeutic response, suggesting that the benefits of treatment most likely overshadow the salutary effects of the V64I polymorphism.

Original languageEnglish (US)
Pages (from-to)861-865
Number of pages5
JournalClinical Infectious Diseases
Volume39
Issue number6
DOIs
StatePublished - Sep 15 2004

Fingerprint

Disease Progression
HIV-1
Genotype
Population
Therapeutics
Virus Diseases
Cohort Studies
HIV

ASJC Scopus subject areas

  • Immunology

Cite this

Philpott, S., Burger, H., Tarwater, P. M., Lu, M., Gange, S. J., Anastos, K., ... Weiser, B. (2004). CCR2 genotype and disease progression in a treated population of HIV type 1-infected women. Clinical Infectious Diseases, 39(6), 861-865. https://doi.org/10.1086/423386

CCR2 genotype and disease progression in a treated population of HIV type 1-infected women. / Philpott, Sean; Burger, Harold; Tarwater, Patrick M.; Lu, Ming; Gange, Stephen J.; Anastos, Kathryn; Cohen, Mardge; Greenblatt, Ruth M.; Kovacs, Andrea; Minkoff, Howard; Young, Mary; Miotti, Paolo; Dupuis, Michelle; Weiser, Barbara.

In: Clinical Infectious Diseases, Vol. 39, No. 6, 15.09.2004, p. 861-865.

Research output: Contribution to journalArticle

Philpott, S, Burger, H, Tarwater, PM, Lu, M, Gange, SJ, Anastos, K, Cohen, M, Greenblatt, RM, Kovacs, A, Minkoff, H, Young, M, Miotti, P, Dupuis, M & Weiser, B 2004, 'CCR2 genotype and disease progression in a treated population of HIV type 1-infected women', Clinical Infectious Diseases, vol. 39, no. 6, pp. 861-865. https://doi.org/10.1086/423386
Philpott, Sean ; Burger, Harold ; Tarwater, Patrick M. ; Lu, Ming ; Gange, Stephen J. ; Anastos, Kathryn ; Cohen, Mardge ; Greenblatt, Ruth M. ; Kovacs, Andrea ; Minkoff, Howard ; Young, Mary ; Miotti, Paolo ; Dupuis, Michelle ; Weiser, Barbara. / CCR2 genotype and disease progression in a treated population of HIV type 1-infected women. In: Clinical Infectious Diseases. 2004 ; Vol. 39, No. 6. pp. 861-865.
@article{bc70b0208c9b45b9bee2662cc216b0b8,
title = "CCR2 genotype and disease progression in a treated population of HIV type 1-infected women",
abstract = "Both antiretroviral therapy and the human coreceptor polymorphism CCR2-V64I slow progression of human immunodeficiency virus type 1 (HIV-1) disease. To examine the effect of V64I on disease progression in patients receiving therapy, we determined CCR2 genotypes in the Women's Interagency HIV Study cohort. We studied 2047 HIV-1-infected women, most of whom initiated treatment during the study. No association was seen between CCR2 genotype and either disease progression or therapeutic response, suggesting that the benefits of treatment most likely overshadow the salutary effects of the V64I polymorphism.",
author = "Sean Philpott and Harold Burger and Tarwater, {Patrick M.} and Ming Lu and Gange, {Stephen J.} and Kathryn Anastos and Mardge Cohen and Greenblatt, {Ruth M.} and Andrea Kovacs and Howard Minkoff and Mary Young and Paolo Miotti and Michelle Dupuis and Barbara Weiser",
year = "2004",
month = "9",
day = "15",
doi = "10.1086/423386",
language = "English (US)",
volume = "39",
pages = "861--865",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - CCR2 genotype and disease progression in a treated population of HIV type 1-infected women

AU - Philpott, Sean

AU - Burger, Harold

AU - Tarwater, Patrick M.

AU - Lu, Ming

AU - Gange, Stephen J.

AU - Anastos, Kathryn

AU - Cohen, Mardge

AU - Greenblatt, Ruth M.

AU - Kovacs, Andrea

AU - Minkoff, Howard

AU - Young, Mary

AU - Miotti, Paolo

AU - Dupuis, Michelle

AU - Weiser, Barbara

PY - 2004/9/15

Y1 - 2004/9/15

N2 - Both antiretroviral therapy and the human coreceptor polymorphism CCR2-V64I slow progression of human immunodeficiency virus type 1 (HIV-1) disease. To examine the effect of V64I on disease progression in patients receiving therapy, we determined CCR2 genotypes in the Women's Interagency HIV Study cohort. We studied 2047 HIV-1-infected women, most of whom initiated treatment during the study. No association was seen between CCR2 genotype and either disease progression or therapeutic response, suggesting that the benefits of treatment most likely overshadow the salutary effects of the V64I polymorphism.

AB - Both antiretroviral therapy and the human coreceptor polymorphism CCR2-V64I slow progression of human immunodeficiency virus type 1 (HIV-1) disease. To examine the effect of V64I on disease progression in patients receiving therapy, we determined CCR2 genotypes in the Women's Interagency HIV Study cohort. We studied 2047 HIV-1-infected women, most of whom initiated treatment during the study. No association was seen between CCR2 genotype and either disease progression or therapeutic response, suggesting that the benefits of treatment most likely overshadow the salutary effects of the V64I polymorphism.

UR - http://www.scopus.com/inward/record.url?scp=4544250408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544250408&partnerID=8YFLogxK

U2 - 10.1086/423386

DO - 10.1086/423386

M3 - Article

C2 - 15472820

AN - SCOPUS:4544250408

VL - 39

SP - 861

EP - 865

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -